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EDITORIAL
Myopenia—a new universal term for muscle wasting
Kenneth Fearon & William J. Evans & Stefan D. Anker
# The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract A universal term describing the presence of
clinically relevant muscle wasting that warrants medical
intervention is required. The term sarcopenia might be used
in this context. However, common use now means that
sarcopenia is more often regarded as synonymous with age-
associated muscle wasting in the elderly. We suggest the
term “myopenia” to indicate the presence of clinically
relevant muscle wasting due to any illness and at any age.
This term would translate well into any language and is
sufficiently specific if appropriately defined. We suggest to
define myopenia as a clinically relevant degree of muscle
wasting that is associated either with impaired functional
capacity and/or with increased risk of morbidity or
mortality. The precise cut-points to define myopenia may
be different in various diseases. Myopenia could be
diagnosed when a certain degree of muscle wasting over
time has occurred (for instance, at least 5% in 6–12 months)
or when muscle mass is below a certain threshold level (for
instance, the <5th centile of healthy 30-year-olds or a fat-
free mass index <16 kg/m2 for men and <15 kg/m2 for
women). Future studies need to refine these in a disease-
specific manner and link them to degrees of functional
impairment that are clinically relevant and/or to degrees of
risk of morbid or fatal events.
Keywords Muscle wasting .Myopenia . Cachexia .
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It is difficult to treat a disease one cannot define. And
certainly, it is impossible to get an approvable indication for a
new medication for a disease one cannot define. A clear
definition and classification system is thus a key requirement
for the development and use of new drugs. This not only
allows for the identification of patients for clinical trials but
also provides the basis for epidemiological studies to allow
the community at large to appreciate the prevalence and
impact of the condition on health outcomes. Osteoporosis is a
condition that has passed through all these phases, including
the development of the term osteopenia [1].
The rash of recent publications on the definition and
classification of cachexia and sarcopenia [2–5] seems to
herald the same process for the second component of the
musculoskeletal system. Skeletal muscle is among the most
plastic of tissues in the human body. The gain and loss of
skeletal muscle occur for a number of reasons under a
variety of different physiological and metabolic conditions.
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Skeletal muscle is important for whole-body protein
metabolism as it is the main reservoir for amino acids to
maintain protein synthesis in tissues and organs, particular-
ly in any situation where amino acid absorption is reduced
[6]. The loss of skeletal muscle mass and function is an
important clinical consequence of disease, immobilization/
reduced activity, poor nutrition, the use of specific
medications, and aging. This loss of muscle has a number
of metabolic and functional consequences that are too often
not appreciated or unrecognized by clinicians.
What term should we use to delineate the phenomenon
of a patient having lost enough skeletal muscle mass to
have decreased quality of life or increased risk of morbidity
and mortality sufficient to merit therapeutic intervention?
The word sarcopenia (loss of flesh) would, at first glance,
seem to be the ideal term. Baumgartner defined this
originally as a skeletal muscle mass two standard deviations
below that of the mean of healthy 30-year-olds [7]. Since
then, the world of geriatric medicine has validated this
cutoff as a useful risk index that relates loss of muscle mass
in the elderly to clinically important events such as falls or
the loss of independence [8]. The changing demography of
Western countries (with a doubling in the over 80s in the
next 20 years and the rising costs of nursing home care) has
galvanized the urgency to find therapy for such “sarcope-
nia,” and in many circles, the term sarcopenia is now
synonymous with the progressive muscle wasting observed
specifically in the elderly [9] (only occasionally is it to
describe muscle wasting in defined illnesses like cancer
[10] or renal disease). Indeed, sarcopenia is defined in
Wikipedia as “the degenerative loss of skeletal muscle mass
and strength associated with aging” (http://en.wikipedia.
org/wiki/Sarcopenia). There are now proposals to refine the
original concept and develop diagnostic criteria that
encompass both loss of muscle mass and loss of function
(e.g. reduced gait speed).
The development of better diagnostic criteria for the
specific muscle wasting associated with the elderly is only
to be applauded. However, can we readily use such criteria in
younger patients? The natural loss of skeletal muscle mass is
age dependent and progressive (0.5–1% loss per year after the
age of 25). If we apply diagnostic criteria developed for those
over 65 to patients who are aged 40, we will naturally
underestimate the magnitude of their deficit. Furthermore,
when we try to quantify the degree of muscle loss as a
component of a complex syndrome such as cachexia, if we
use the term and diagnostic criteria set out for sarcopenia in
the elderly, are we going to clarify or confuse the situation?
Are we not further confusing the medical and scientific
communities when the term sarcopenia is used also for muscle
wasting in cancer, chronic heart failure, and lung or kidney
disease? In all these different conditions, the degree of muscle
wasting requiring intervention may be different.
We therefore come to a dichotomy. Can we use
sarcopenia as a blanket term for muscle wasting at any
age and from any cause or do we accept that sarcopenia be
reserved for (clinically significant) muscle wasting of the
elderly? We suggest to do the latter, and it seems this is
where the scientific and medical ship is cruising to.
Consequently, we need a different catch-all term to indicate
the presence of muscle wasting due to any illness and at
any age.
The first term coming to mind is the term “muscle
wasting” itself. This term is self-explanatory. However, the
term is already used to describe a pathophysiologic process
and not used or accepted to describe a medical entity
requiring intervention. Possibly the biggest problem with
this term is that it translates poorly into other languages,
which has hindered widespread acceptance outside groups
communicating in English. Therefore, we propose to
introduce a new term: “myopenia” (Fig. 1). This term
would translate well into any language and is sufficiently
specific, if appropriately defined.
Myopenia is a clinically relevant degree of muscle
wasting that is associated either with impaired functional
capacity and/or with increased risk of morbidity or
mortality. The precise cut-points to define presence of
myopenia may be specific to a particular disease or
condition. Myopenia can be diagnosed when a certain
degree of muscle loss over time has occurred (for instance,
at least 5% in 6–12 months) or when muscle mass is below
a certain threshold level. For the latter, for instance, this
could be a muscle mass below the 5th centile of healthy 30-
year-olds or a fat-free mass index <16 kg/m2 for men and
<15 kg/m2 for women as suggested for COPD patients to
identify patients with poor functional status and higher
mortality risk [11, 12]. This approach would be analogous
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Fig. 1 Diseases that can cause clinically significant muscle wasting, i.
e., myopenia
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to the approach used in the body weight component of the
consensus definition of cachexia [13, 14].
Future studies need to refine these cut-points in a
disease-specific manner linking these cut-points to degrees
of functional impairment that are clinically relevant and/or
to degrees of risk of morbid or fatal events. A staging of
degrees of myopenia appears possible as well.
We hope that, with this proposal, more clarity in
communication is possible. We believe that the choice of
the term myopenia can fit logically into the nomenclature
that is developing for different kinds of wasting diseases
including cachexia and sarcopenia. Of course, our proposal
is open for discussion, and we look forward to it!
Acknowledgment All authors comply with the guidelines of ethical
authorship and publishing in the Journal of Cachexia, Sarcopenia and
Muscle [15].
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Silverman SL, Cummings SR, Consensus Panel of the ASBMR,
ISCD, and NOF. Recommendations for the clinical evaluation of
agents for treatment of osteoporosis: consensus of an expert panel
representing the American Society for Bone and Mineral Research
(ASBMR), the International Society for Clinical Densitometry
(ISCD), and the National Osteoporosis Foundation (NOF). J Bone
Miner Res. 2008;23:159–65.
2. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia:
European consensus on definition and diagnosis: report of the
European Working Group on Sarcopenia in Older People. Age
Ageing. 2010;39:412–23.
3. Muscaritoli M, Anker SD, Argiles J, et al. Consensus definition of
sarcopenia, cachexia and pre-cachexia: joint document elaborated
by Special Interest Groups (SIG) “cachexia-anorexia in chronic
wasting diseases” and “nutrition in geriatrics”. Clin Nutr.
2010;29:154–9.
4. Evans WJ, Morley JE, Argiles J, et al. Cachexia: a new definition.
Clin Nutr. 2008;27:793–9.
5. Fearon K, Strasser F, Anker S et al. Definition and classification
of cancer cachexia: an international consensus. Lancet Oncol.
2011 (in press)
6. Wolfe RR. The underappreciated role of muscle in health and
disease. Am J Clin Nutr. 2006;84:475–82.
7. Baumgartner RN, Koehler KM, Gallagher D, et al. Epidemiology
of sarcopenia among the elderly in New Mexico. Am J Epidemiol.
1998;147:755–63.
8. Janssen I, Baumgartner RN, Ross R, et al. Skeletal muscle
cutpoints associated with elevated physical disability risk in older
men and women. Am J Epidemiol. 2004;159:413–21.
9. von Haehling S, Morley JA, Anker SD. An overview of
sarcopenia: facts and numbers on prevalence and clinical impact.
J Cachexia Sarcopenia Muscle. 2010;1:129–33.
10. Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB,
Martin L, et al. Prevalence and clinical implications of sarcopenic
obesity in patients with solid tumours of the respiratory and
gastrointestinal tracts: a population-based study. Lancet Oncol.
2008;9:629–35.
11. Baarends EM, Schols AM, Mostert R, Wouters EF. Peak
exercise response in relation to tissue depletion in patients with
chronic obstructive pulmonary disease. Eur Respir J.
1997;10:2807–13.
12. Schols AM, Broekhuizen R, Weling-Scheepers CA, Wouters EF.
Body composition and mortality in chronic obstructive pulmonary
disease. Am J Clin Nutr. 2005;82:53–9.
13. Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge D,
et al. Cachexia: a new definition. Clin Nutr. 2008;27:793–9.
14. von Haehling S, Anker SD. Cachexia as a major underestimated
and unmet medical need: facts and numbers. J Cachexia
Sarcopenia Muscle. 2010;1:1–5.
15. von Haehling S, Morley JE, Coats AJS, Anker SD. Ethical
guidelines for authorship and publishing in the Journal of
Cachexia, Sarcopenia and Muscle. J Cachexia Sarcopenia Muscle.
2010;1:7–8.
J Cachexia Sarcopenia Muscle (2011) 2:1–3 3
